These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2554501)

  • 21. Low-molecular-weight heparins for unstable angina. A better mousetrap?
    Waters D; Azar RR
    Circulation; 1997 Jul; 96(1):3-5. PubMed ID: 9236404
    [No Abstract]   [Full Text] [Related]  

  • 22. Heparin and its biocompatibility.
    Stiekema JC
    Clin Nephrol; 1986; 26 Suppl 1():S3-8. PubMed ID: 2435441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinolytic guidelines in diabetes.
    Sharma GV; Mukerjee DK; Sasahara AA
    Geriatrics; 1982 Apr; 37(4):38-42, 46. PubMed ID: 7060947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin in the prophylaxis and treatment of venous thromboembolism.
    Thomas DP
    Semin Hematol; 1978 Jan; 15(1):1-17. PubMed ID: 341325
    [No Abstract]   [Full Text] [Related]  

  • 25. When can the patient with deep venous thrombosis begin to ambulate?
    Aldrich D; Hunt DP
    Phys Ther; 2004 Mar; 84(3):268-73. PubMed ID: 14984299
    [No Abstract]   [Full Text] [Related]  

  • 26. Low-molecular-weight heparin for PE.
    Grimm KJ; French L
    J Fam Pract; 1997 Dec; 45(6):467-8. PubMed ID: 9420575
    [No Abstract]   [Full Text] [Related]  

  • 27. Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations.
    Pineo GF; Hull RD
    Med Clin North Am; 1998 May; 82(3):587-99. PubMed ID: 9646781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
    Del Bono R; Martini G; Volpi R
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):950-9. PubMed ID: 21845806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can the bleeding potential of low molecular weight heparins be assessed and minimized in postsurgery prophylaxis?
    Toulemonde F
    Semin Thromb Hemost; 1991 Oct; 17(4):351-5. PubMed ID: 1666455
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapy of thromboses with low-molecular-weight heparins].
    Haas S; Haas P
    Wien Med Wochenschr; 1999; 149(2-4):39-45; discussion 45. PubMed ID: 10378321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comment requested by the editorial staff].
    Haas S
    Chirurg; 2002 Dec; 73(12):1204. PubMed ID: 12617084
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of venous thromboembolic disease using low molecular weight CY216 heparin in patients with high risk of hemorrhage].
    Prandoni P; Vigo M; Tropeano PF; Carletti E; Corbetti F; Antonello G; Cuppini S
    Ann Ital Med Int; 1988; 3(3):213-9. PubMed ID: 2856354
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
    Ruiz Manzano J; Monreal M
    Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
    [No Abstract]   [Full Text] [Related]  

  • 35. [Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study].
    Faivre R; Neuhart E; Kieffer Y; Bassand JP; Maurat JP
    J Mal Vasc; 1987; 12 Suppl B():145-6. PubMed ID: 2834488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D; Chambefort V; Decousus H
    Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract]   [Full Text] [Related]  

  • 37. Fibrinolytic and thrombolytic parameters in patients with deep vein thrombosis treated by low molecular weight and standard heparin.
    Faivre R; Neuhart E; Mirshahi M; Mirshahi M; Soria C; Soria J; Bassand JP; Caen JP; Maurat JP
    Semin Thromb Hemost; 1989 Oct; 15(4):435-9. PubMed ID: 2554504
    [No Abstract]   [Full Text] [Related]  

  • 38. Does low molecular weight heparin cause less bleeding?
    Thomas DP
    Thromb Haemost; 1997 Dec; 78(6):1422-5. PubMed ID: 9423787
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategy for the development of the low molecular weight heparin fraction CY 216 in the prevention of postoperative deep vein thromboses in general surgery.
    Toulemonde F
    Semin Thromb Hemost; 1989 Oct; 15(4):395-400. PubMed ID: 2554500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.
    Hirsh J; Siragusa S; Cosmi B; Ginsberg JS
    Thromb Haemost; 1995 Jul; 74(1):360-3. PubMed ID: 8578485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.